This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 1991 Dec;23(6):2977-83.

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine

J Fung¹, K Abu-Elmagd, A Jain, R Gordon, A Tzakis, S Todo, S Takaya, M Alessiani, A Demetris, O Bronster, et al.

Affiliations

PMID: 1721333
PMCID: PMC2950613

Clinical Trial

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine

J Fung et al. Transplant Proc. 1991 Dec.

. 1991 Dec;23(6):2977-83.

Authors

J Fung¹, K Abu-Elmagd, A Jain, R Gordon, A Tzakis, S Todo, S Takaya, M Alessiani, A Demetris, O Bronster, et al.

Affiliation

¹ Dept. of Surgery, University of Pittsburgh School of Medicine, Pennsylvania 15213.

PMID: 1721333
PMCID: PMC2950613

No abstract available

PubMed Disclaimer

Figures

Fig 1 — Fig 1
Comparison of the patient survival curves for all FK 506- and CyA-randomized patients.

Fig 2 — Fig 2
Comparison of the graft survival for the original FK 506- and CyA-ranoomized liver allografts.

Fig 3 — Fig 3
The percentage of patients in each group who remained rejection free is plotted against the number of months posttransplant for both CyA and FK 506 patients.

Fig 4 — Fig 4
The mean doses of prednisone per day is charted against the time posttranspiant for CyA and FK 506 groups. For the CyA group, two curves are shown, one being for those patients who still remain on CyA vs the group that was converted to FK 506. The percentage of patients in each group who are off all steroids is shown at each time point.

See this image and copyright information in PMC

Similar articles

FK 506 versus cyclosporine in pediatric liver transplantation.
Tzakis AG, Reyes J, Todo S, Green M, Ohya T, Jain A, Abu-Elmagd K, Alessiani M, Fung JJ, Starzl TE. Tzakis AG, et al. Transplant Proc. 1991 Dec;23(6):3010-5. Transplant Proc. 1991. PMID: 1721343 Free PMC article. Clinical Trial. No abstract available.
Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
Bismuth H. Bismuth H. Transplant Proc. 1995 Feb;27(1):45-9. Transplant Proc. 1995. PMID: 7533415 Clinical Trial. No abstract available.
A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.
U.S. Multicenter FK506 Liver Study Group. U.S. Multicenter FK506 Liver Study Group. N Engl J Med. 1994 Oct 27;331(17):1110-5. doi: 10.1056/NEJM199410273311702. N Engl J Med. 1994. PMID: 7523946 Clinical Trial.
Neoral is superior to FK 506 in liver transplantation.
Levy GA. Levy GA. Transplant Proc. 1998 Aug;30(5):1812-5. doi: 10.1016/s0041-1345(98)00442-4. Transplant Proc. 1998. PMID: 9723293 Review. No abstract available.
Clinical use of FK 506 in liver transplantation.
Klintmalm GB. Klintmalm GB. Transplant Proc. 1996 Apr;28(2):974-6. Transplant Proc. 1996. PMID: 8623484 Review.

See all similar articles

Cited by

Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.
Todo S, Fung JJ, Starzl TE, Tzakis A, Doyle H, Abu-Elmagd K, Jain A, Selby R, Bronsther O, Marsh W, et al. Todo S, et al. Ann Surg. 1994 Sep;220(3):297-308; discussion 308-9. doi: 10.1097/00000658-199409000-00006. Ann Surg. 1994. PMID: 7522431 Free PMC article. Clinical Trial.
Prevention of transplant rejection: current treatment guidelines and future developments.
Perico N, Remuzzi G. Perico N, et al. Drugs. 1997 Oct;54(4):533-70. doi: 10.2165/00003495-199754040-00003. Drugs. 1997. PMID: 9339960 Review.
Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery.
Yasutsune T, Kawakami N, Hirano K, Nishimura J, Yasui H, Kitamura K, Kanaide H. Yasutsune T, et al. Br J Pharmacol. 1999 Feb;126(3):717-29. doi: 10.1038/sj.bjp.0702339. Br J Pharmacol. 1999. PMID: 10188984 Free PMC article.
Liver transplantation at the University of Pittsburgh, 1984 to 1990.
Gordon RD, Fung J, Tzakis AG, Todo S, Stieber A, Bronsther O, Martin M, Van Thiel DH, Starzl TE. Gordon RD, et al. Clin Transpl. 1991:105-17. Clin Transpl. 1991. PMID: 1726458 Free PMC article. Clinical Trial.
Adverse effects of FK 506 overdosage after liver transplantation.
Alessiani M, Cillo U, Fung JJ, Irish W, Abu-Elmagd K, Jain A, Takaya S, Van Thiel D, Starzl TE. Alessiani M, et al. Transplant Proc. 1993 Feb;25(1 Pt 1):628-34. Transplant Proc. 1993. PMID: 7679825 Free PMC article. No abstract available.

See all "Cited by" articles

References

1. Starzl TE, Todo S, Fung J, et al. Lancet. 1989;2:1000. - PMC - PubMed
1. Todo S, Fung JJ, Demetris AJ, et al. Transplant Proc. 1990;22:13. - PMC - PubMed
1. Fung JJ, Todo S, Jain A, et al. Transplant Proc. 1990;22:6. - PMC - PubMed
1. Kino T, Hatanaka H, Miyata S, et al. J Antibiot (Tokyo) 1987;40:1256. - PubMed
1. Siekierka JJ, Hung SHY, Poe M, et al. Nature. 1989;341:755. - PubMed

Publication types

Actions
Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information